The inhibitory results of NVP-BEZ235 in CLL correspond with the effectiveness of NVP-BEZ235 treatment in other AKT/mTOR-driven cancer types, as well as with previous data demonstrating suppression of eIF4G activity and 4E-BP1 phosphorylation in AML [69, 71]. Here, AKT1 is linked to acute myeloid leukemia.